Abstract
Changes in myelin ultrastructure under experimental Parkinsonism in the tissues of the medulla oblongata and striatum were performed under experimental Parkinsonism induced by rotenone administration in 30 adult rats of the Wistar line. Clinico-electromyographic studies were performed on patients with Parkinson's disease with a stage of disease 2.0 -3.0 (Hoehn a. Yahr).
Efficacy of Cerebrolysin has been shown to correct myelin abnormalities to elucidate the effect on the muscle reflex response to irritation of sensitive nerve fibres of the mixed nerve with subsequent monosynaptic activation of motor neurons and spinal cord neurons. One of the mechanisms associated with myelin damage in Parkinsonism is the development of mitochondrial dysfunction, in any case, its ultrastructural component. The use of Cerebrolysin leads to a significant elimination of mitochondrial dysfunction and myelin damage. It can be assumed that the positive effect of the drug lies in the antioxidant effect, which, in turn, effect the transmembrane conductivity, which should be considered one of the neuroprotective effects of the drug.
Keywords: experimental Parkinsonism; Parkinson's disease; myelin; medulla oblongata; sriatum; mitochondrial dysfunction; transmembrane conductivity; cerebrolysin.
Publisher
State Institution - D. F. Chebotarev Institute of Gerontology NAMS of Ukraine
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference30 articles.
1. Boshkovski, T.; Cohen-Adad, J.; Misic B.; Arnulf, I.; Corvol, J-Ch. et al. The Myelin-Weighted Connectome in Parkinson’s disease. Mov Disord 2021. 37, 4, 724-733. https://doi.org/10.1002/mds.28891
2. Dean, D. C.; Sojkova, J.; Hurley, S.; Kecskemeti, S.; Okonkwo, O. et al. Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study. PLoS One 2016. 11, 10, p e0163774. https://doi.org/10.1371/journal.pone.0163774
3. Tully, M.; Shi, R. New insights in the pathogenesis of multiple sclerosis - role of acrolein in neuronal and myelin damage. Int J Mol Sci 2013. 14, 10, p 20037-20047. https://dx.doi.org/10.3390%2Fijms141020037
4. Mankovska, I.; Rozova, K.; Karaban, I.; Gonchar, O., Bratus, L. Pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease: approaches and perspectives. Drug Target Rev 2018, 3, p 49-53.
5. Baumeister, T. R.; Kim, J. L.; Zhu, M.; McKeown, M. J. White matter myelin profiles linked to clinical subtypes of Parkinson’s disease. J Magn Reson Imaging 2019, 50, 1, p 164–174. https://doi.org/10.1002/jmri. 26543